Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Information Technology Index Fund ETF (VGT) vs Viatris Inc (VTRS) Price & Performance

Vanguard Information Technology Index Fund ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Vanguard Information Technology Index Fund ETF vs Viatris Inc — how do they compare? Vanguard Information Technology Index Fund ETF trades at $127.98 (market cap $170.20B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 8.5× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Vanguard Information Technology Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Information Technology Index Fund ETF for 129 Days and Viatris Inc for 57 Days on average.

VGTVTRS
Market Cap
$170.20B$20.03B
Volume
5,132,88314,109,977
52-Week High
$129.79$18.27
52-Week Low
$83.59$9.74
Typical Hold Time
129 Days57 Days
Sector
—Health
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Information Technology Index Fund ETF

VGT trades at $127.25, down 1.64% on the day but maintains a bullish technical outlook with strong moving average support. The ETF's concentration in leading technology companies like Nvidia, Apple, and Microsoft provides exposure to AI and cloud computing growth trends. Recent articles highlight VGT's historical performance of over 17% annual returns over the past two decades.

The outlook remains positive given technology sector momentum and VGT's low expense ratio advantage. Key risks include sector concentration and potential AI market slowdowns. Current technical positioning near pivot point resistance at $128 suggests potential for breakout if momentum continues.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.

The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

VGT
87% Buy13% Sell
Avg holding period · 129 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Vanguard Information Technology Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.

Read more on VGT →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →